Page last updated: 2024-11-13

heparitin sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53477715
MeSH IDM0010194

Synonyms (16)

Synonym
heparitin monosulfate
heparan sulphate
heparatan sulfate
heparitin
heparan n-sulfate
n-acetylheparan sulfate
heparitin sulfate
suleparoid
hhs 5
tavidan
heparitin sulphate
n-acetylheparan sulphate
heparatan sulphate
heparan n-sulphate
alpha-idosane
heparitin monosulphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It was well tolerated and no adverse effects occurred."( Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
Dawes, J; Moelker, HC; Stiekema, JC; Toeberich, H; Van Dinther, TG; Vinchenzo, A; Wijnand, HP, 1989
)
0.28
" Furthermore, the E4 isoform of the 22 kDa fragment is significantly more toxic than the same fragment derived from the E3 isoform, suggesting the possibility of a direct role of apoE-associated neurotoxicity in the pathophysiology of Alzheimer's disease."( Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated.
Crutcher, KA; Harmony, JA; Marques, MA; Tolar, M, 1997
)
0.3
" 1250 anti-Xa Units of Org 10172 once daily is both safe and as effective as 5000 IU of heparin sodium twice daily given for DVT prophylaxis in patients with acute ischaemic stroke of recent onset."( A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke.
Abedinpour, F; Berberich, R; Dumas, R; Egberts, JF; Gregoire, F; Jerkovic, M; Kutnowski, M; Nikolic, I; Woitinas, F; Zoeckler, S, 1994
)
0.29
"Danaparoid sodium appears to be an efficient and safe treatment in critically ill patients with HIT."( Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Guyotat, D; Mahul, P; Mazet, E; Mismetti, P; Reynaud, J; Tardy, B; Tardy-Poncet, B, 1999
)
0.3
"8%) survived, 7 having suffered from a serious adverse event."( Safety and efficacy of danaparoid (Orgaran) use in children.
Bidlingmaier, C; Girisch, M; Kurnik, K; Magnani, HN, 2006
)
0.33
"Heparan sulfate (HS) has been found associated with amyloid deposits, including the toxic amyloid-beta (Abeta) peptide aggregates in cerebral vasculature and neuronal tissues in patients with Alzheimer's disease."( Heparan sulfate mediates amyloid-beta internalization and cytotoxicity.
Lannfelt, L; Li, JP; Lindahl, U; O'Callaghan, P; Sandwall, E; Zhang, X, 2010
)
0.36
" Primary endpoints included the type and severity of adverse events, presence of anti-rhHNS antibodies in the CSF and serum, and changes in laboratory values."( Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Alexanderian, D; de Ruijter, J; Heap, F; Jones, SA; Marchal, JP; Nestrasil, I; Rust, S; Shapiro, E; Tump, E; Wijburg, FA, 2021
)
0.62
" All patients experienced at least one treatment-emergent adverse event (TEAE), most being mild or moderate in severity."( Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Alexanderian, D; de Ruijter, J; Heap, F; Jones, SA; Marchal, JP; Nestrasil, I; Rust, S; Shapiro, E; Tump, E; Wijburg, FA, 2021
)
0.62
" In addition, the pre-fibrils formed by β-casein were toxic because they induced the death and apoptosis of HC11 cells, as well as the inflammation of mammary gland of rats."( The Influence of Heparan Sulfate on Breast Amyloidosis and the Toxicity of the Pre-fibrils Formed by β-casein.
An, Y; Dong, Q; Liu, J; Su, J; Sun, B; Wang, J; Xie, H, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" No pharmacokinetic data are available to better understand its potential as a new therapeutic modality for diseases with excess local and systemic histamine, like anaphylaxis, urticaria or mastocytosis."( Human diamine oxidase cellular binding and internalization in vitro and rapid clearance in vivo are not mediated by N-glycans but by heparan sulfate proteoglycan interactions.
Boehm, T; Borth, N; Gludovacz, E; Jilma, B; Petroczi, K; Pollheimer, J; Resch, M; Salminen, TA; Schosserer, M; Schuetzenberger, K; Tillmann, K; Vakal, S; Virgolini, N; Vondra, S, 2021
)
0.62
" However, the factors influencing the pharmacokinetic properties of HS-based therapeutics remain unknown."( Investigation of the pharmacokinetic properties of synthetic heparan sulfate oligosaccharides.
Arnold, K; Liu, J; Lucas, A; Wang, Z; Xu, Y; Zamboni, W, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"Given the wide spread clinical use of ceramic-based bone void fillers, we sought to determine the efficacy of an FDA-approved β-tricalcium phosphate bone graft substitute (JAX™) in combination with a carboxymethyl cellulose (CMC) handling agent that included a particular heparan glycosaminoglycan (GAG) variant, herein referred to as HS3."( Repair of segmental ulna defects using a β-TCP implant in combination with a heparan sulfate glycosaminoglycan variant.
Chatterjea, A; Cool, SM; Fenwick, SA; Hosaka, YZ; Hui, JH; Lee, JJL; Lim, ZXH; Murali, S; Nurcombe, V; Rai, B; Sawyer, AA; Tan, TC, 2015
)
0.42
"Synthetic bone grafts and demineralized bone matrices are gaining prominence as alternatives to autologous and allogeneic bone grafts and are frequently administered in granular form, necessitating their combination with a handling agent."( Repair of segmental ulna defects using a β-TCP implant in combination with a heparan sulfate glycosaminoglycan variant.
Chatterjea, A; Cool, SM; Fenwick, SA; Hosaka, YZ; Hui, JH; Lee, JJL; Lim, ZXH; Murali, S; Nurcombe, V; Rai, B; Sawyer, AA; Tan, TC, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability of Orgaran following subcutaneous administration was determined on the basis of plasma anti-Xa and IIaGI activities and the NoA-GAG fraction concentrations."( Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof, M; de Boer, A; Magnani, HN; Stiekema, JC, 1992
)
0.28
" We conclude that the bioavailability of VEGF may be regulated at the genetic level by alternative splicing that determines whether VEGF will be soluble or incorporated into a biological reservoir and also through proteolysis following plasminogen activation."( Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.
Ferrara, N; Houck, KA; Leung, DW; Rowland, AM; Winer, J, 1992
)
0.28
" We propose that restriction of bFGF bioavailability by binding to ECM and local regulation of its release, provides a novel mechanism for regulation of capillary blood vessel growth in normal and pathological situations."( Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis.
Bar-Shavit, R; Bashkin, P; Fuks, Z; Ishai-Michaeli, R; Korner, G; Vlodavsky, I, 1990
)
0.28
" The absolute bioavailability of Org 10172 as measured by plasma anti-Xa activity, glycosaminoglycuronans with no affinity to antithrombin III (NoA-GAG) and thrombin generation inhibiting activity approached 100% in both sexes."( Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
Dawes, J; Moelker, HC; Stiekema, JC; Toeberich, H; Van Dinther, TG; Vinchenzo, A; Wijnand, HP, 1989
)
0.28
" Our findings should aid the design of synthetic oligosaccharides aimed at improving the bioavailability of bFGF when administered in vivo as a therapeutic agent."( Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor.
Coltrini, D; Grazioli, G; Naggi, A; Oreste, P; Presta, M; Rusnati, M; Zoppetti, G, 1994
)
0.29
" Second, because many of the changes induced by TGF beta resembled changes reported to occur during the formation of various kinds of subcapsular cataracts, the results suggest that detailed studies of factors that influence the ability of lens cells to respond to TGF beta and the bioavailability of TGF beta in the ocular media may provide important insights into the etiology of some forms of cataract."( Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta.
Chamberlain, CG; Hales, AM; Liu, J; McAvoy, JW, 1994
)
0.29
" Moreover, the concerted action of proteases that degrade the protein core and heparanases that remove the heparan sulfate may modulate the bioavailability of the growth factor."( The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.
Iozzo, RV; Murdoch, AD; Underwood, PA; Whitelock, JM, 1996
)
0.29
" We suggest that FGFR-2 is the preferred receptor for FGF4 under restricted HS conditions and that the bioavailability of structurally distinct HS motifs may differentially control receptor specificity of FGF4 in vivo."( Heparin differentially regulates the interaction of fibroblast growth factor-4 with FGF receptors 1 and 2.
Aviezer, D; Safran, M; Yayon, A, 1999
)
0.3
" The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and predictable anticoagulant response (avoiding the need for dose adjustment or laboratory monitoring in most patients), and a low risk of heparin-induced thrombocytopenia and osteoporosis."( Low molecular weight heparins and heparinoids.
Eikelboom, JW; Hankey, GJ, 2002
)
0.31
" Synthetic, selective, and direct inhibitors to FXa, such as DX-9065a, are highly potent and orally bioavailable antithrombotic agents that have demonstrated an improved side effect profile, probably by allowing sufficient thrombin to remain for platelet activation and normal hemostasis, while preventing pathological thrombus formation."( Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Ieko, M; Koike, T; Naito, S; Nakabayashi, T; Tarumi, T; Yoshida, M, 2006
)
0.33
" Because both PAPP-A and proMBP are expressed ubiquitously, this model may be applicable to many tissues in which insulin-like growth factor bioavailability is locally regulated."( Cell surface detachment of pregnancy-associated plasma protein-A requires the formation of intermolecular proteinase-inhibitor disulfide bonds and glycosaminoglycan covalently bound to the inhibitor.
Conover, CA; Dagnaes-Hansen, F; Glerup, S; Kløverpris, S; Laursen, LS; Oxvig, C; Thiel, S, 2007
)
0.34
"We have demonstrated that modifications to increase bioavailability of chemically modified heparins have little effect on their efficacy as beta-secretase inhibitors."( Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.
Edwards, EA; Patey, SJ; Turnbull, JE; Yates, EA, 2008
)
0.35
" Fondaparinux has excellent bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without anticoagulant monitoring."( Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bauer, KA; Donati, MB; Gould, M; Hirsh, J; Samama, MM; Weitz, JI, 2008
)
0.35
"Angiogenesis is crucial for the progression of colorectal carcinomas in which the bioavailability of Vascular Endothelial Growth Factor (VEGF) plays a major role."( VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.
David, G; de Jonge-Muller, ES; Ferreira, V; Fontijn, RD; Hawinkels, LJ; Hommes, DW; Lamers, CB; Sier, CF; van Duijn, W; Verspaget, HW; Zuidwijk, K, 2008
)
0.35
" Degradation of HS proteoglycans decreased NO bioavailability through an increase in O(2)(-) production as indicated by fluorescent signals of dihydroethidium (DHE) and its area fraction (209+/-24% increase) and also removed extracellular O(2)(-) dismutase (ecSOD) (67+/-9% decrease)."( Role of glycocalyx in flow-induced production of nitric oxide and reactive oxygen species.
Kassab, GS; Kumagai, R; Lu, X, 2009
)
0.35
"Control of the bioavailability of the growth factor TGFbeta is essential for tissue formation and homeostasis, yet precisely how latent TGFbeta is incorporated into the extracellular matrix is unknown."( Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta.
Baldock, C; Baldwin, AK; Chaudhry, SS; Chiu, M; Choudhury, R; Kielty, CM; Massam-Wu, T; McGovern, A; Shuttleworth, CA, 2010
)
0.36
" These findings establish a critical role of Sulfs in promoting GDNF signaling and support a model in which Sulfs regulate the bioavailability of GDNF by enzymatically remodeling HS 6-O-desulfation to release GDNF from matrix sequestration."( Expression regulation and function of heparan sulfate 6-O-endosulfatases in the spermatogonial stem cell niche.
Ai, X; Fine, A; Jain, S; Kreidberg, JA; Langsdorf, A; Schumacher, V; Shi, X; Taglienti, M; Tran, T; Zaia, J, 2011
)
0.37
" These results show that bone marrow-derived HS effectively supports bone formation, and suggest its applicability in bone repair by selectively facilitating the delivery and bioavailability of BMP-2."( Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2).
Bramono, DS; Cool, SM; Lim, ZX; Ling, L; Murali, S; Nurcombe, V; Poh, WT; Rai, B; Stein, GS; van Wijnen, AJ, 2012
)
0.38
" Fondaparinux exhibits complete bioavailability when administered subcutaneously, has a longer half-life than LMWHs, and is given once daily by subcutaneous injection in fixed doses, without coagulation monitoring."( Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Baglin, TP; Garcia, DA; Samama, MM; Weitz, JI, 2012
)
0.38
" Bioavailability and pharmacokinetic behaviour and characteristics of these oligosaccharides vary significantly depending on the origin/nature of the substrate (heparin or heparan sulphate-like glycosaminoglycans), the source of enzyme and method of preparation."( Microbial heparin/heparan sulphate lyases: potential and applications.
Banga, J; Mishra, V; Tripathi, CK, 2012
)
0.38
" Therefore, Sulfs may increase the bioavailability of canonical Wnts for Frizzled receptor and LRP5/6 interaction in lipid raft, which may in turn antagonize non-canonical Wnt signaling."( Heparan sulfate 6-O-endosulfatases (Sulfs) coordinate the Wnt signaling pathways to regulate myoblast fusion during skeletal muscle regeneration.
Ai, X; Shi, X; Tran, TH; Zaia, J, 2012
)
0.38
" Extracellular levels of sLRP-1 can thus increase the half-life of TIMP-3 in the extracellular space, controlling the bioavailability of TIMP-3 to inhibit metalloproteinases."( Differential regulation of extracellular tissue inhibitor of metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein receptor-related protein 1.
Emonard, H; Enghild, JJ; Nagase, H; Scilabra, SD; Strickland, DK; Thøgersen, I; Troeberg, L; Yamamoto, K, 2013
)
0.39
" Any future exploitation of the TGF-β cytokines in the therapy of chronic diseases will need to fully consider their interactions with glycosaminoglycans and the implications of this in terms of their bioavailability and biological activity."( Heparin, Heparan Sulphate and the TGF-β Cytokine Superfamily.
Mulloy, B; Rider, CC, 2017
)
0.46
" Besides a remodelling of the extracellular matrix, HPSE increases the bioavailability of pro-angiogenic mediators, such as HS-associated vascular endothelial growth factor (VEGF), thereby contributing to metastatic niche formation."( Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Bendas, G; Benkel, T; Gockel, L; Grundmann, M; Hoß, SG; Ilan, N; Kostenis, E; Schlesinger, M; Schwarz, S; Vlodavsky, I, 2018
)
0.48
" Here we present evidence that chemical PEGylation of dnCXCL8 with 20 kDa and 40 kDa PEG does not significantly interfere with GAG binding affinity, nor does it influence the mutant's disabled chemotaxis function, while it strongly improved bioavailability and serum half-life of the chemokine mutant."( PEGylation of a glycosaminoglycan-binding, dominant-negative CXCL8 mutant retains bioactivity in vitro and in vivo.
Adage, T; Gerlza, T; Jeremic, D; Krieger, E; Kungl, A; Trojacher, C, 2020
)
0.56
" This review summarizes recent findings on the roles of HPSE in activation, inhibition, or bioavailability of key signaling molecules such as AKT, VEGF, MAPK-ERK, and EGFR, which are known regulators of common viral infections in immune and non-immune cell types."( Heparanase, cell signaling, and viral infections.
Koganti, R; Shukla, D; Suryawanshi, R, 2020
)
0.56
" HS sequesters a number of secreted growth factors and cytokines, controlling their bioavailability to the target cells, suggesting that HS is an important regulator of the extracellular matrix (ECM) and a key player in the cell-cell and cell-microenvironment communication during prostate morphogenesis and physiology."( Heparan sulfate fine-tunes stromal-epithelial communication in the prostate gland.
Barbosa, GO; Biancardi, MF; Carvalho, HF, 2021
)
0.62
" However, the specific molecular requirements controlling the bioavailability of BMPs in the extracellular matrix (ECM) are not yet fully understood."( Targeting of bone morphogenetic protein complexes to heparin/heparan sulfate glycosaminoglycans in bioactive conformation.
Baumann, U; Correns, A; Doherr, S; Gebauer, JM; Grobe, K; Imhof, T; Koch, M; Lütke, S; Mörgelin, M; Sengle, G; Sonntag, N; Spanou, CES; Wohl, AP, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Rapid elimination of some of these components may explain why twice daily dosing is required for optimal thrombosis prophylaxis with Orgaran."( Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof, M; de Boer, A; Magnani, HN; Stiekema, JC, 1992
)
0.28
" The studies have established a potentially optimal dosage and treatment regimen and have provided information for the development of a large randomized trial."( Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group.
Adams, HP; Biller, J; Clarke, W; Woolson, RF, 1992
)
0.28
" In the presence of Org 10172 there was a reduction in the AUC of digoxin during one dosing interval after the seventh digoxin tablet from 20 to 17 ng."( Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
Breimer, DD; Danhof, M; de Boer, A; Moolenaar, AJ; Stiekema, JC, 1991
)
0.28
" However, allergen-induced release of GAG from the basophils of atopic individuals exhibited a different time-course and dose-response from that of histamine, and may occur at least in part by a different mechanism."( Release of highly-sulphated glycosaminoglycans and histamine from human basophils.
Barnetson, RS; Dawes, J; MacGregor, IR; Reilly, KM; Yap, PL, 1988
)
0.27
" Since there was no apparent dose effect gradient, it was decided to pool the data from all three dosing blocks: this analysis showed that Org 10172 increased geometric mean blood loss during the first 2 days after surgery from 10."( The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.
Gallus, A; Magnani, H; Marshall, V; Morris, M; Murphy, W; Nacey, J; Sutherland, P, 1989
)
0.28
"4 unit Org 10172 dosage was as effective as heparin in preventing fibrin deposition."( Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
Büller, HR; Henny, CP; Mooy, MC; Surachno, S; ten Cate, H; ten Cate, JW; Wilmink, JM, 1985
)
0.27
" Medium conditioned over each cell type was then tested in dose-response assay against both explants and dissociated motoneurones."( Motoneurone survival and neuritic outgrowth promoted by different cell types in embryonic muscle.
Bennett, MR; Nurcombe, V; Tout, S, 1985
)
0.27
" Both heparin effects exhibited similar dose-response curves with half-maximal effects at approximately 5 micrograms/ml heparin."( Heparin induces endothelial extracellular matrix alterations and barrier dysfunction.
Gerbitz, KD; Guretzki, HJ; Olgemöller, B; Schleicher, E, 1994
)
0.29
" The differences observed for control and chlorate-treated cells in the dose-response curves for stimulation of DNA synthesis and receptor binding correlated directly, suggesting that receptors are equally capable of eliciting a mitogenic signal under both conditions."( Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate.
Fannon, M; Nugent, MA, 1996
)
0.29
" Heparin therapy adapted to the result of the activated cephalin time (two to three times the control value) and oral vitamin K antagonists with a dosage adapted to keep the International Normalized Ratio between 2 and 3 is the safest and most effective treatment to date."( [Anticoagulant therapy in pulmonary embolism].
Augusseau-Richard, MP; Charbonnier, B; Dessenne, X; Pacouret, G; Pagot, O, 1995
)
0.29
" Exact dosage schedules are provided."( [Loss of extremities caused by heparin-induced thrombocytopenia].
Leffringhausen, W; Scherlitzky, L; Wenzl, ME, 1996
)
0.29
" The inactive X allele, however, is hypermethylated in leukocytes, presumably reflecting early X inactivation events that become important for gene dosage in expressing lineages."( DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1.
D'Esposito, M; D'Urso, M; Gartler, SM; Hansen, RS; Huber, R; Mazzarella, R; Pengue, G; Pilia, G; Schlessinger, D; Strazzullo, M, 1999
)
0.3
" Danaparoid, a low-molecular-weight heparinoid, and once-daily enoxaparin are recently released dosage forms that have been evaluated as pharmacoprophylaxis for DVT after hip replacement surgery."( Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery.
Wade, WE, 1999
)
0.3
"The effects of dosing time on the anticoagulant activity of unfractionated heparin, low molecular weight heparin (nadroparin) and danaproid were investigated."( A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
Abrial, D; Blanc, A; Bouchut, C; Buisson, B; Decousus, H; Laporte-Simitsidis, S; Mismetti, P; Réhailia, M,
)
0.13
" The present tendency is to do without biological monitoring for adapting dosage in favour of optimisation of the impact in a given situation, perhaps, above all, with respect to the preceding problem."( [New antithrombotic drugs (excluding plasminogen activators].
Lecompte, T, 2001
)
0.31
" However, optimal dosing regimens have not been established in all cases."( Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Jeske, WP; Walenga, JM, 2002
)
0.31
" Two studies have compared danaparoid with UFH in the prophylaxis of DVT following acute ischaemic stroke; twice daily danaparoid was significantly superior to UFH whereas there was no significant difference between a once-daily dosage and UFH."( Danaparoid: a review of its use in thromboembolic and coagulation disorders.
Ibbotson, T; Perry, CM, 2002
)
0.31
" Treatment of astrocytes with chondroitinase ABC revealed a growth-promoting effect of CS on lateral glia but treatment with exogenous CS-4 indicated a U-shaped dose-response curve for CS."( Sulfated proteoglycans as modulators of neuronal migration and axonal decussation in the developing midbrain.
Carvalho, SL; Cavalcante, LA; Garcia-Abreu, J; Mendes, FA; Moura Neto, V; Onofre, G; Silva, LC; Weissmüller, G, 2003
)
0.32
"It is emphasized that the possibility of clinically significant antibody cross-reactivity and that low or intermediate dosage may be inadequate when using danaparoid in therapy of HIT."( Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal, S; Manhas, AH; Rice, L; Udden, M, 2003
)
0.32
" If the pretest probability of HIT is high, heparin should be stopped and an alternative anticoagulant started at full dosage unless there are significant contraindications while laboratory tests are performed."( The management of heparin-induced thrombocytopenia.
Davidson, S; Keeling, D; Watson, H, 2006
)
0.33
" Clinical outcomes of these case reports of patients given danaparoid because of suspected or confirmed HIT appear to be comparable with those reported by others who used direct thrombin inhibitors, especially when a sufficient danaparoid dosing intensity was used in patients with isolated HIT."( Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Gallus, A; Magnani, HN, 2006
)
0.33
" HS was harvested from conditioned media, cell surface and matrix compartments of postconfluent (differentiating) MC3T3-E1 osteoblasts and dosed back onto preconfluent MC3T3-E1 cells."( Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2.
Cool, SM; Jackson, RA; Murali, S; Nurcombe, V; Stein, GS; van Wijnen, AJ, 2007
)
0.34
" Recent data indicate that the approved dosing regimens of the direct thrombin inhibitors are too high, especially in ICU patients."( Heparin-induced thrombocytopenia in intensive care patients.
Greinacher, A; Selleng, K; Warkentin, TE, 2007
)
0.34
" Important drug-specific limitations and dosing and monitoring guidelines must be respected for patient safety."( The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.
Prechel, M; Walenga, JM, 2008
)
0.35
" However, before attributing thrombotic complications to danaparoid cross-reactivity, it is crucial to verify that the patients received the recommended danaparoid dosage regimen."( Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases.
Bauters, A; Elalamy, I; Ffrench, P; Lasne, D; Tardy, B; Tardy-Poncet, B; Wolf, M, 2009
)
0.35
"5% pregnancies respectively at a dosing intensity of 1000 to 7500 U/day."( An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran).
Magnani, HN, 2010
)
0.36
" The treatment started with a smaller therapeutic doses of danaparoid than recommended of 750 U intravenous bolus and was followed by continuous infusions of 100 U per 1 h and intravenous gammaglobulins in full dosage for four days."( [Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report].
Antonijević, N; Djunić, I; Djurasinović, V; Elezović, I; Gradinac, S; Kovac, M; Tomin, D; Vidović, A,
)
0.13
" At concentrations higher than the "therapeutic" levels, the dose-response curve in the Ks assay became very steep for lepirudin while those were shallow for the others."( The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
Bark, N; Blombäck, M; He, S; Johnsson, H; Wallén, NH, 2010
)
0.36
"The number of myeloid lineage-committed progenitor cells was increased at low dosage of HS as illustrated by an increase in the total number of colony-forming cells (CFC) and colonies of erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) precursors."( The effect of human bone marrow stroma-derived heparan sulfate on the ex vivo expansion of human cord blood hematopoietic stem cells.
Bramono, DS; Cool, SM; Murali, S; Nurcombe, V; Rider, DA, 2011
)
0.37
" Dose-response curves and heparin-Sepharose binding suggested Ad·hFX has greater affinity for HSPGs than does Ad·mFX."( Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate.
Elashoff, D; Esko, JD; Herschman, HR; Lawrence, R; Zaiss, AK, 2011
)
0.37
" Preliminary pharmacokinetic analyses also revealed significant increases in half-life following iv dosing, ultimately supporting less frequent dosing regimens in preclinical tumor models compared with other HS mimetics."( Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.
Bytheway, I; Davis, K; Dredge, K; Ferro, V; Hammond, E; Handley, P; Harenberg, J; Johnstone, KD; Karoli, T; Li, CP; Liu, L; Rowley, J; Sarimaa, L; Wimmer, N, 2012
)
0.38
" In a search for genes with a comparable phenotype we found that a mutation in the known dosage compensation gene dpy-21 showed similar axon guidance defects as zfp-1 or lin-35 mutants."( A network of HSPG core proteins and HS modifying enzymes regulates netrin-dependent guidance of D-type motor neurons in Caenorhabditis elegans.
Flibotte, S; Gysi, S; Hengartner, MO; Moerman, DG; Rhiner, C, 2013
)
0.39
" Exogenous dosing with HS7(+ve) alone significantly enhanced the formation of new blood vessels with potencies comparable to VEGF165."( Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy.
Bell, TJ; Bhakoo, K; Cool, SM; Hinkley, SF; Koo, CY; Murali, S; Nurcombe, V; Poon, S; Wang, C; Yeong, H, 2014
)
0.4
" Outflow tract alignment is sensitive to the dosage of Ext1."( Heparan Sulfate Biosynthesis Enzyme, Ext1, Contributes to Outflow Tract Development of Mouse Heart via Modulation of FGF Signaling.
Cao, P; Chen, Y; Pan, Y; Wang, Z; Wu, JL; Yang, Z; Zhang, R, 2015
)
0.42
" A moderate dosage of CS (5%) led to the highest amount of neocartilage deposition."( A comparative study of chondroitin sulfate and heparan sulfate for directing three-dimensional chondrogenesis of mesenchymal stem cells.
Wang, T; Yang, F, 2017
)
0.46
" Patients were treated with RGTA (Cacicol; Thea, Paris, France) instilled at a dosage of one drop on alternate days."( Topical Treatment of Persistent Epithelial Defects with a Matrix Regenerating Agent.
Sevik, MO; Toker, E; Turhan, SA, 2018
)
0.48
"Plasma samples were used for HA dosage and urine for quantification of CS and HS from forty-four cancer patients and fourteen controls."( Prospective Evaluation of Chondroitin Sulfate, Heparan Sulfate and Hyaluronic Acid in Prostate Cancer.
da Silva, MNR; Martins, JRM; Mendes, A; Pinhal, MADS; Tobias-Machado, M,
)
0.13
" Danaparoid is an alternative anticoagulant used in patients on HD with HIT but its dosing recommendations in obese patients on HD are relatively scarce."( Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
Castelino, RL; Kairaitis, L; Maddula, M; Sud, K; Tarafdar, S, 2019
)
0.51
"We report a case of a 48-year-old morbidly obese patient who received weight-based dosing of danaparoid for HD with monitoring of anti-Xa activity."( Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
Castelino, RL; Kairaitis, L; Maddula, M; Sud, K; Tarafdar, S, 2019
)
0.51
"The report provides evidence that the manufacturer's recommendations on dosing danaparoid based on body weight may lead to sub-optimal therapeutic benefit and highlight the need for higher than recommended weight-based dosing in obese individuals on dialysis."( Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.
Castelino, RL; Kairaitis, L; Maddula, M; Sud, K; Tarafdar, S, 2019
)
0.51
" To assess dose-response relationships, we performed IA with increasing concentrations of versican and VET with increasing concentrations of thrombomodulin."( Glycocalyx components affect platelet function, whole blood coagulation, and fibrinolysis: an in vitro study suggesting a link to trauma-induced coagulopathy.
Britten, MW; Dirkmann, D; Lümers, L; Peters, J; Tominaga, K, 2021
)
0.62
" Declines from baseline in Bayley Scales of Infant Development, Third Edition or Kaufman Assessment Battery for Children, Second Edition, Nonverbal Index developmental quotient scores were evident at all rhHNS dosing groups: -17."( Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
Alexanderian, D; de Ruijter, J; Heap, F; Jones, SA; Marchal, JP; Nestrasil, I; Rust, S; Shapiro, E; Tump, E; Wijburg, FA, 2021
)
0.62
" In addition to clinical monitoring, GAG dosage has been commonly used to evaluate ERT efficacy."( Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
Capitani, F; D'Avanzo, F; Gabrielli, O; Galeotti, F; Maccari, F; Mantovani, V; Rigon, L; Salvalaio, M; Tomanin, R; Volpi, N; Zanetti, A, 2022
)
0.72
" A pilot study utilizing every other week dosing in two animals supports further evaluation of less frequent dosing."( Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
Agrawal, V; Aguilera, A; Alcozie, S; Baridon, B; Bullens, S; Bunting, S; Christianson, TM; Crawford, BE; Fong, S; Giaramita, A; Gil, G; Gorostiza, O; Hague, C; Handyside, B; Jones, S; Lawrence, R; Lebowitz, JH; Lo, MJ; Magat, J; Mangini, L; Parker, M; Pungor, E; Roy, SM; Slabodkin, I; Tiger, PMN; Vincelette, J; Vitelli, C; Wendt, DJ; Woloszynek, JC; Wong, H; Yeung, N; Zhou, Y, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Metabolic pathways of fibroblasts1718

Research

Studies (6,660)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901262 (18.95)18.7374
1990's1903 (28.57)18.2507
2000's1520 (22.82)29.6817
2010's1419 (21.31)24.3611
2020's556 (8.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 5.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index5.80 (24.57)
Research Supply Index8.85 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (5.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials118 (1.73%)5.53%
Reviews721 (10.57%)6.00%
Case Studies211 (3.09%)4.05%
Observational9 (0.13%)0.25%
Other5,764 (84.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]